247 related articles for article (PubMed ID: 30177821)
1. Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.
Ackerman ME; Das J; Pittala S; Broge T; Linde C; Suscovich TJ; Brown EP; Bradley T; Natarajan H; Lin S; Sassic JK; O'Keefe S; Mehta N; Goodman D; Sips M; Weiner JA; Tomaras GD; Haynes BF; Lauffenburger DA; Bailey-Kellogg C; Roederer M; Alter G
Nat Med; 2018 Oct; 24(10):1590-1598. PubMed ID: 30177821
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
[TBL] [Abstract][Full Text] [Related]
3. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
4. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
5. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.
Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ
J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519
[TBL] [Abstract][Full Text] [Related]
6. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates.
Warren J
J Med Primatol; 2002 Aug; 31(4-5):237-56. PubMed ID: 12390546
[TBL] [Abstract][Full Text] [Related]
7. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
[TBL] [Abstract][Full Text] [Related]
8. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
9. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
[TBL] [Abstract][Full Text] [Related]
10. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.
Brown EP; Dowell KG; Boesch AW; Normandin E; Mahan AE; Chu T; Barouch DH; Bailey-Kellogg C; Alter G; Ackerman ME
J Immunol Methods; 2017 Apr; 443():33-44. PubMed ID: 28163018
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
13. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Xiao P; Zhao J; Patterson LJ; Brocca-Cofano E; Venzon D; Kozlowski PA; Hidajat R; Demberg T; Robert-Guroff M
J Virol; 2010 Jul; 84(14):7161-73. PubMed ID: 20444898
[TBL] [Abstract][Full Text] [Related]
14. Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy.
Palermo RE; Patterson LJ; Aicher LD; Korth MJ; Robert-Guroff M; Katze MG
J Virol; 2011 Jan; 85(2):1099-116. PubMed ID: 21068249
[TBL] [Abstract][Full Text] [Related]
15. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.
Flatz L; Cheng C; Wang L; Foulds KE; Ko SY; Kong WP; Roychoudhuri R; Shi W; Bao S; Todd JP; Asmal M; Shen L; Donaldson M; Schmidt SD; Gall JG; Pinschewer DD; Letvin NL; Rao S; Mascola JR; Roederer M; Nabel GJ
J Virol; 2012 Aug; 86(15):7760-70. PubMed ID: 22593152
[TBL] [Abstract][Full Text] [Related]
16. Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.
Mörner A; Jansson M; Bunnik EM; Schøller J; Vaughan R; Wang Y; Montefiori DC; Otting N; Bontrop R; Bergmeier LA; Singh M; Wyatt RT; Schuitemaker H; Biberfeld G; Thorstensson R; Lehner T
J Virol; 2011 Jul; 85(13):6442-52. PubMed ID: 21490092
[TBL] [Abstract][Full Text] [Related]
17. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
18. Use of nonhuman primate models to develop mucosal AIDS vaccines.
Genescà M; Miller CJ
Curr HIV/AIDS Rep; 2010 Feb; 7(1):19-27. PubMed ID: 20425054
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.
Vargas-Inchaustegui DA; Tuero I; Mohanram V; Musich T; Pegu P; Valentin A; Sui Y; Rosati M; Bear J; Venzon DJ; Kulkarni V; Alicea C; Pilkington GR; Liyanage NP; Demberg T; Gordon SN; Wang Y; Hogg AE; Frey B; Patterson LJ; DiPasquale J; Montefiori DC; Sardesai NY; Reed SG; Berzofsky JA; Franchini G; Felber BK; Pavlakis GN; Robert-Guroff M
Clin Immunol; 2014 Aug; 153(2):308-22. PubMed ID: 24907411
[TBL] [Abstract][Full Text] [Related]
20. A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques.
Musich T; Thovarai V; Venzon DJ; Mohanram V; Tuero I; Miller-Novak LK; Helmold Hait S; Rahman MA; Hunegnaw R; Huiting E; Yuan W; O'hUigin C; Hoang T; Sui Y; LaBranche C; Montefiori D; Bear J; Rosati M; Bissa M; Berzofsky JA; Pavlakis GN; Felber BK; Franchini G; Robert-Guroff M
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
